Trubion Signs Leukemia Drug Agreement Worth up to $196 Million

Trubion will get $20 million upfront from Redwood City, Calif.-based Facet and may get up to $176 million more for the worldwide development and commercialization of its chronic lymphocytic leukemia drug if certain development, regulatory and sales milestones are met.
Puget Sound Business Journal